Merigolix

Merigolix
Clinical data
Other names	HS-10518; NCE-403; SKI-2670; TU-2670
Routes of; administration	Oral
Drug class	GnRH antagonist
Identifiers
	IUPAC name 4-[[(1R)-2-[1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-2,4-dioxo-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[7H-furo[3,4-d]pyrimidine-5,4'-piperidine]-3-yl]-1-phenylethyl]amino]butanoic acid;
CAS Number	1454272-94-6;
PubChem CID	71727383;
ChemSpider	128922028;
UNII	RS62JYV9LX;
ChEMBL	ChEMBL5314469;
Chemical and physical data
Formula	C36H35F7N4O6
Molar mass	752.687 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCC12C3=C(CO2)N(C(=O)N(C3=O)C[C@@H](C4=CC=CC=C4)NCCCC(=O)O)CC5=C(C=CC=C5F)C(F)(F)F)CC6=CC=C(O6)C(F)(F)F;
	InChI InChI=1S/C36H35F7N4O6/c37-26-9-4-8-25(35(38,39)40)24(26)19-46-28-21-52-34(13-16-45(17-14-34)18-23-11-12-29(53-23)36(41,42)43)31(28)32(50)47(33(46)51)20-27(22-6-2-1-3-7-22)44-15-5-10-30(48)49/h1-4,6-9,11-12,27,44H,5,10,13-21H2,(H,48,49)/t27-/m0/s1; Key:LJPSGSMPGVITHK-MHZLTWQESA-N;

Merigolix (INNTooltip International Nonproprietary Name; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids.^[1]^[2]^[3]^[4]^[5] It is taken by mouth.^[1] The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical.^[1]^[2] As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids.^[1]^[2]

References

1 2 3 4 5 "Merigolix". AdisInsight. 28 October 2024. Retrieved 24 February 2025.
1 2 3 "Delving into the Latest Updates on Merigolix with Synapse". Synapse. 22 February 2025. Retrieved 24 February 2025.
↑ Tukun FL, Olberg DE, Riss PJ, Haraldsen I, Kaass A, Klaveness J (December 2017). "Recent Development of Non-Peptide GnRH Antagonists". Molecules. 22 (12): 2188. doi:10.3390/molecules22122188. PMC 6149776. PMID 29232843.
↑ Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G (2019). "Uterine fibroids: an update on current and emerging medical treatment options". Therapeutics and Clinical Risk Management. 15: 157–178. doi:10.2147/TCRM.S147318. PMC 6350833. PMID 30774352.
↑ Angioni S, D'Alterio MN, Daniilidis A (2021). "Highlights on Medical Treatment of Uterine Fibroids". Current Pharmaceutical Design. 27 (36): 3821–3832. doi:10.2174/1381612826666210101152820. PMID 33388011.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information.

[AdisInsight-1] 1 2 3 4 5 "Merigolix". AdisInsight. 28 October 2024. Retrieved 24 February 2025.

[Synapse-2] 1 2 3 "Delving into the Latest Updates on Merigolix with Synapse". Synapse. 22 February 2025. Retrieved 24 February 2025.

[TukunOlbergRiss2017-3] Tukun FL, Olberg DE, Riss PJ, Haraldsen I, Kaass A, Klaveness J (December 2017). "Recent Development of Non-Peptide GnRH Antagonists". Molecules. 22 (12): 2188. doi:10.3390/molecules22122188. PMC 6149776. PMID 29232843.

[FarrisBastianelliRosato2019-4] Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G (2019). "Uterine fibroids: an update on current and emerging medical treatment options". Therapeutics and Clinical Risk Management. 15: 157–178. doi:10.2147/TCRM.S147318. PMC 6350833. PMID 30774352.

[AngioniD'AlterioDaniilidis2021-5] Angioni S, D'Alterio MN, Daniilidis A (2021). "Highlights on Medical Treatment of Uterine Fibroids". Current Pharmaceutical Design. 27 (36): 3821–3832. doi:10.2174/1381612826666210101152820. PMID 33388011.

[1]

[2]

[3]

[4]

[5]

This page was redesigned at the edge.

Merigolix

See also

References